Progress in iron chelators: the report of the 53rd annual meeting of American Society of Hematology / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 73-76, 2012.
Article
in Chinese
| WPRIM
| ID: wpr-472024
ABSTRACT
Chelation therapy could remove transfusional iron burden. Three chelators are currently available, including deferoxamine, deferiprone, and deferasirox, which can be used as monotherapy or in combination.Several factors must be considered in the design of optimal and individualized chelation regimens,which include chelator availability and its properties,degree of organ-specific iron loading,ongoing transfusional iron burden, and patient preference. Comparative effectiveness trials may help to determine the ideal strategy. This article reviews latest research presented at the 53rd annual meeting of the American Society of Hematology (ASH) on the use of iron chelators.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Leukemia & Lymphoma
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS